瑞銀:降中升控股(0881.HK)評級至“沽售” 目標價下調至23.2港元
瑞銀髮表研究報告,指中升控股(0881.HK)
股價在過去12個月累升約90%,認為股價已反映市場對其獨特品牌結構及穩定的售後業務的樂觀看法。該行相信,市場對中升的預期已升至相當高的水平,但並無考慮如新型冠狀病毒肺炎疫情等的潛在風險。瑞銀表示,中升目前估值較其5年平均市盈率高出一個標準差,而本次新型冠狀病毒肺炎疫情或會對集團新車及售後業務(維修收入下降)產生短期挑戰。
該行下調對中升控股評級,由“
中性
”降至“
沽售
”,目標價由26.6港元降至23.2港元。另外,又下調集團2019年至2021年各年每股盈測介乎5%至16%,以反映該行調低對平治的銷售預測。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.